

CORRECTION

Open Access



Correction to: Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer's disease

Laura E. Donovan¹, Eric B. Dammer², Duc M. Duong³, John J. Hanfelt⁴, Allan I. Levey¹, Nicholas T. Seyfried^{1,3*} and James J. Lah^{1*}

Correction to: *Alz Res Therapy* 5, 32 (2013)
<https://doi.org/10.1186/alzrt186>

It has recently come to our attention that a paper we published in 2013 in *Alzheimer's Research & Therapy* never included the tables (Tables 1, 2 and 3) and supplemental tables (Additional file 1) in the published manuscript [1]. This must have been an oversight at the proof or production stage.

Tables 1, 2 and 3 are shown below.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13195-021-00839-y>.

Additional file 1: Supplementary Table S1. 1009 proteins identified by unique peptides (top group members) identified in platelet membrane proteome from either a probable AD pool or a cognitive normal pool. **Supplementary Table S2.** 1957 total proteins (all potential group members) identified in platelet membrane proteome from either a probable AD pool or a cognitive normal pool. **Supplementary Table S3.** 144 potential marker proteins identified in platelet membrane proteome from a probable AD pool (FDR < 7%). **Supplementary Table 4.** 10 Classes incorporating 97 potentially novel AD biomarkers quantified in platelet membrane pools.

Author details

¹Department of Neurology and Center for Neurodegenerative Disease, Emory University School of Medicine, 615 Michael Street NE, Atlanta, GA

The original article can be found online at <https://doi.org/10.1186/alzrt186>.

* Correspondence: nseyfri@emory.edu; jlal@emory.edu

¹Department of Neurology and Center for Neurodegenerative Disease, Emory University School of Medicine, 615 Michael Street NE, Atlanta, GA 30322, USA

Full list of author information is available at the end of the article



© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

30322, USA. ²Department of Human Genetics, Emory University School of Medicine, 615 Michael Street NE, Atlanta, GA 30322, USA. ³Department of Biochemistry, Emory University School of Medicine, 1510 Clifton Road NE, Atlanta, GA 30322, USA. ⁴Department of Biostatistics and Bioinformatics, Emory University School of Medicine, 1518 Clifton Road NE, Atlanta, GA 30322, USA.

Published online: 18 May 2021

Reference

1. Donovan LE, Dammer EB, Duong DM, et al. Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer's disease. *Alz Res Therapy*. 2013;5:32. <https://doi.org/10.1186/alzrt186>.

Table 1 Participants

Controls			Probable Alzheimer's Disease (AD)		
Case #	Age	MMSE ^a	Case #	Age	MMSE ^a
1	75	28	1	83	20
2	72	29	2	77	18
3	74	30	3	90	11
4	67	29	4	83	20
5	73	29	5	82	24
6	60	30	6	61	12
7	69	30	7	55	25
AVERAGES:		70.00 29.3		75.86	18.6

Cases in bold were pooled for proteomic analysis

Bold type-face indicates cases pooled for proteomic analysis

^aMMSE mini mental status exam, clinical measurement of cognitive function

Table 3 Overlap of AD platelet membrane protein changes with previously proposed mechanistic and diagnostic biomarkers

Mean log ₂ (AD/CT)	R1 vs R2 CV, SD%	Symbol	Protein Name
2.46	14%	MGAT4B	mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isozyme B
-1.23	52%	VPS13C	vacuolar protein sorting 13 homolog C (<i>S. cerevisiae</i>)
-1.24	20%	AGPS	alkylglycerone phosphate synthase
-1.92	15%	FTL	ferritin, light polypeptide
-1.97	7.0%	IGF1R	insulin-like growth factor 1 receptor

Table 2 DAVID analysis of changes in proteins associated with platelet-specific secretion

Mean log ₂ (AD/CT)	R1 vs R2 CV, SD%	Symbol	Protein Name	Ontology Groups
-1.70	0.6%	FGA	fibrinogen alpha chain	A, B, C, E, F
-2.03	7.5%	FGB	fibrinogen beta chain	A, B, C, E, F
-1.69	1.5%	FGG	fibrinogen gamma chain	A, B, C, E, F
-2.02	1.9%	VWF	von Willebrand factor	A, B, C, E
-1.23	39%	PROS1	protein S (alpha)	B, C, E, F
-1.19	59%	FN1	fibronectin 1	B, C, D, F
-1.19	41%	SERPINA1	serpin peptidase inhibitor, clade A (alpha-1 antitrypsin, antitrypsin), member 1	B, C, E
-1.47	31%	SPARC	secreted protein, acidic, cysteine-rich (osteonectin)	B, C, F
-2.05	0.9%	THBS1	thrombospondin 1	B, C, F
1.47	1.2%	GP9	glycoprotein IX (platelet)	B, C
-2.82	2.9%	C4BPA	complement component 4 binding protein, alpha	D, E
-1.24	94%	SERPINE1	serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1	E, F
-1.83	66%	TF	transferrin	C
-1.65	10%	HP	haptoglobin-related protein; haptoglobin	D
-1.33	31%	SUSD1	sushi domain containing 1	D